Get started
Author

Stefanie M. Howaldt

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023 · Geert D’Haens, Marla Dubinsky, et al. · New England Journal of Medicine · 398
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
2014 · D. Rampton, J. Folkersen, et al. · Haematologica · 325
PDF
Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease
1996 · Stefan Schreiber, Stefanie Howaldt, et al. · New England Journal of Medicine · 201
PDF
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
2015 · J Szebeni, S Fishbane, et al. · British Journal of Pharmacology · 164
PDF
Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program
2015 · Christoph Gasche, Tariq Ahmad, et al. · Inflammatory Bowel Diseases · 137
PDF
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
2021 · Silvio Danese, Jean-Frederic Colombel, et al. · The Lancet. Gastroenterology & hepatology · 103
PDF
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · The Lancet. Gastroenterology & hepatology · 103
PDF
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.
1997 · S Schreiber, J Hämling, et al. · Gut · 103
PDF
Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study
2014 · Florian Beigel, Niels Teich, et al. · Journal of Crohn s and Colitis · 77
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study
2012 · K.R. Herrlinger, M. Diculescu, et al. · Journal of Crohn s and Colitis · 76
A Randomised, Double-blind, Placebo-controlled Trial ofTrichuris suisova in Active Crohn’s disease
2016 · Jürgen Schölmerich, Klaus Fellermann, et al. · Journal of Crohn s and Colitis · 73
PDF
Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD: the Randomized, Controlled ThromboVIT Trial
2013 · Stefanie Kulnigg-Dabsch, Werner Schmid, et al. · Inflammatory Bowel Diseases · 70
Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study
2016 · C. Schmidt, T. Ahmad, et al. · Alimentary Pharmacology & Therapeutics · 49
PDF
Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial
2021 · Stefanie Howaldt, Eugeni Domènech, et al. · Inflammatory Bowel Diseases · 39
PDF
Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
1994 · S Schreiber, S Howaldt, et al. · Gut · 31
PDF
Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease
2011 · Sandra Wenger, Susanna Nikolaus, et al. · Journal of Crohn s and Colitis · 20
Cost-Effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany
1999 · E. S. Dietrich, U. Joseph, et al. · Infection · 16
Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency
2016 · Bernd Bokemeyer, Annette Krummenerl, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 15
Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area
2020 · Constanze H. Waggershauser, Cornelia Tillack‐Schreiber, et al. · Alimentary Pharmacology & Therapeutics · 12
PDF
Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study
2025 · Bernd Bokemeyer, Sandra Plachta-Danielzik, et al. · Journal of Crohn s and Colitis · 11
867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
2022 · Marla C. Dubinsky, Peter M. Irving, et al. · Gastroenterology · 11
P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron
2020 · S Howaldt, I Jacob, et al. · Journal of Crohn s and Colitis · 9
PDF
Efficacy, Safety and Tolerability of Vidofludimus in Patients With Inflammatory Bowel Disease: The ENTRANCE Study
2011 · Klaus R. Herrlinger, Mircea M. Diculescu, et al. · Gastroenterology · 9
PDF
Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist
2012 · Olivier Dewit, Xavier Hebuterne, et al. · Gastroenterology · 6
Induction and maintenance of mucosal healing in Crohn’s disease with ustekinumab in clinical practice across all care levels in Germany (MUCUS)
2024 · Daniel C. Baumgart, Andreas Stallmach, et al. · Scientific Reports · 5
Works count: 58
Citation count: 2,090
H-index: 16
I10-index: 21
Year
Topic
Type